Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ASP2215 in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia with FLT3 Mutation: Background and Design of the ADMIRAL Trial

2 Mar 2018

Abstract excerpt

Acute myeloid leukemia (AML) is a heterogeneous disease with cure rates of only 30-40% in patients <60 years old. Cytogenetic and molecular markers have improved our understanding of the different prognostic entities in AML. FLT3 mutations are present in 30-40% of AML cases, conferring a poor prognosis with reduced survival. AXL activates FLT3, impacting adversely on outcome. Both FLT3 and AXL constitute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29498296
DOI: 10.2217/fon-2017-0582

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASP2215 in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia with FLT3 Mutation: Background and Design of the ADMIRAL TrialPMID 29498296Read ↗

Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response StudySemantic proximity Read ↗

Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.Semantic proximity Read ↗

Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.Semantic proximity Read ↗

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.Semantic proximity Read ↗

The clinical development of FLT3 inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Gilteritinib: potent targeting of FLT3 mutations in AML.Semantic proximity Read ↗

Rapid response to avapritinib of acute myeloid leukemia with t(8;21) andKITmutation relapse post allo-HSCTSemantic proximity Read ↗

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.Semantic proximity Read ↗

MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.Semantic proximity Read ↗

Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.Semantic proximity Read ↗

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.